Compare Ecolab Inc. (ECL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Mesoblast Limited — how do they compare? Ecolab Inc. trades at $282.14 (market cap $78.97B), while Mesoblast Limited trades at $14.28 (market cap $1.75B). The key difference: Ecolab Inc. is far larger — about 45.1× Mesoblast Limited's market cap, and Ecolab Inc. pays a 1.04% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Mesoblast Limited for 14 Days on average.
| ECL | MESO | |
|---|---|---|
Market Cap | $78.97B | $1.75B |
Volume | 974,947 | 239,027 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $20.96 |
52-Week Low | $245.73 | $13.19 |
Typical Hold Time | 90 Days | 14 Days |
Enterprise Value | $87.75B | $1.83B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% on the day, with strong analyst support (78% buy ratings) and a $326.38 consensus price target suggesting 17% upside. The stock shows bullish technical signals with support at $275 and resistance at $279. Recent Q2 2026 earnings beat expectations with 9.7% sales growth, while the company maintains dividend aristocrat status with consistent payout increases.
ECL presents a compelling growth story with expanding high-tech and digital segments, though elevated valuation multiples (P/E 37.81) and rising debt from the CoolIT acquisition warrant caution. The essential nature of its hygiene and water management services provides defensive characteristics, while upcoming Q3 earnings on October 27 will be critical for validating growth trajectory.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
